H1N1 Vaccines Market Structure by Size, Valuable Shares, Industry Research, Top Manufacturers, Demand & Forecast Till 2026
SEATTLE, April 09, 2021, (PHARMIWEB) — Global H1N1 Vaccines Market
The H1N1 influenza virus is said to result in an acute viral disease, commonly known as swine flu, which mostly affects the respiratory system of a human being. Swine flu is typically characterized by infection caused by the H1N1 strain. The most common symptoms of swine flu include fever, cough, sore throat, runny or stuffy nose, watery and red eyes, body aches, headache, fatigue, and diarrhea. H1N1 spreads through contact with contaminated air or geographical locations that are infected with the virus. The H1N1 infection may worsen and lead to other chronic respiratory conditions, such as bronchitis, pneumonia, COPD, and sometimes even death due to severe respiratory failure.
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/2056
The H1N1 vaccine is an important innovation that has been intended to tackle the H1N1 pandemic since 2009. Initially, the vaccines developed or available were inactivated monovalent vaccines, which could prevent infection from most of the strains of H1N1. There are two routes of administration, namely, intradermal for inactivated vaccines and intranasal for live attenuated vaccine. Both the routes have shown an efficacy profile and are bioequivalent against preventing H1N1 infection. Thus, the global H1N1 vaccines market holds significant presence across multinational pharmaceutical companies, as well as companies based in several emerging economies around the world.
Global H1N1 Vaccines Market Dynamics
One of the major factors propelling the growth of the global H1N1 vaccines market is the augmented incidence of disease and episodes of pandemic worldwide from the H1N1 infection. According to the World Health Organization’s (WHO) 2018 factsheet estimates, around 290,000 to 650,000 deaths are reported each year resulting from all types of influenza infection (including Influenza A i.e. H1N1). Each year, there are up to three to five million cases of severe illness from viral influenza infection reported globally, as reported by the same source.
Government initiatives, both international and national, intended to tackle the H1N1 pandemic are anticipated to positively impact the global market growth. Health institutions, such as the World Health Organization (WHO), have been acting instrumentally in developing vaccines and supporting the efficient distribution of the vaccine. After the 2009 pandemic of the H1N1 influenza, the U.S. government initiated the US$ 3 billion H1N1 vaccine project, under which it contracted five major companies to develop the appropriate vaccine for the H1N1 influenza. Reportedly, under the WHO’s Global Influenza Surveillance and Response System, the National Influenza Centers and WHO Collaborating Centers are continuously monitoring the influenza viruses circulating in humans, and moreover, updates the composition of the influenza vaccines up to twice a year.
Furthermore, the rising geriatric population worldwide would be another impetus for the growth of the global H1N1 vaccines market. Global population is crossing the age of 60 at an annual rate of 3%, according to the 2017 UN report. Increased age, maximizes the risk of various respiratory tract-related diseases and immune deficiency diseases, thereby enhancing the risk of this infection with a major surge in the incidence rate of the H1N1 virus. Rising awareness among patients about preventive healthcare approaches, such as vaccination, may lead to a higher demand for H1N1 vaccines during the forecast period.
However, the seasonal nature of occurrence of swine flu has led to a meagre revenue generation for many of the key market players. For instance, India-based Serum Institute, which produces intranasal live vaccines to treat swine flu, had to destroy a stock of around 2 million doses in the year 2011, due to lack of demand for the vaccine. On the contrary, if the pandemic arises abruptly, the supply of the vaccine may be delayed due to its slow production, which may negatively affect the health of many patients. Hence, with the constantly evolving nature of the H1N1 virus, the vaccine might turn out to be ineffective in some parts of the world, which could discourage the use of those vaccines.
Global H1N1 Vaccines Market – Regional Insights
North America is expected to lead the global H1N1 vaccines market during the forecast period. Market growth in this region is attributed to the increasing government initiatives aimed at the prevention of the H1N1 infection. The U.S., which faced the major epidemic in 2009, has now strengthened its preventive approach to control the H1N1 outbreak by implementing its vaccination program. According to the statistics released by the Centre for Disease Control and Prevention (CDC) in February 2018, during October 1, 2017 and February 3, 2018, clinical laboratories tested 666,493 specimens for influenza virus, 124,316 (18.7%) of which tested positive for influenza virus. 84.3% of these tested positive for influenza A.
Furthermore, the Asia Pacific market is expected to exhibit the highest CAGR due to the high prevalence of swine flu and increasing awareness about vaccination against H1N1. According to the Ministry of Health and Family Welfare, Government of India, there were 0.1 million cases in India of H1N1 influenza during 2010 to 2017. Continuous changing nature of the virus creates challenges to overcome the H1N1 epidemic. For instance, in 2017, a new Michigan strain of H1N1 swine flu virus was first identified in India. The government of the country has played an important role in tackling the pandemic by spreading awareness about H1N1 vaccine throughout the country. Furthermore, the Government of India has published guidelines for case management of influenza A/H1N1, which categorizes influenza patients into three principal groups, depending on their severity. Vaccination was recommended for the patient group that is highly susceptible to H1N1 fever.
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/2056
Global H1N1 Vaccines Market – Competitive Landscape
The key players involved in the global H1N1 vaccines market are Medimmune, AstraZeneca, GlaxoSmithKline, Novartis, Serum Institute of India, Abbott Healthcare, Sanofi Pasture, CSL Biotherapeutics, Sinovac, ID Biomedical Corporation, Cadila Healthcare, and Lupin Ltd.
Global H1N1 Vaccines Market Taxonomy
On the basis of vaccine type:
- Inactivated Vaccine
- Live Attenuated Vaccine
Based on the route of administration:
- Injectable Vaccine
- Intranasal Vaccine
By distribution channel:
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
On the basis of geography:
- North America
- Latin America
- Asia Pacific
- Middle East
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire